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Abstract
Objective:  To  compare  the  effects  of  intravenous  hyoscine  butylbromide  versus  placebo  on  the
duration of  labor  in  term  pregnancies.
Materials  and  methods:  86  patients  were  selected  and  randomly  assigned  to  receive  intra-
venous hyoscine  butylbromide  (20  mg  twice)  (n  =  43)  or  an  intravenous  placebo  (saline  solution
10 cc)  (n  =  43).  We  evaluated  maternal  adverse  effects,  effects  on  neonatal  Apgar  score,  cer-
vical dilatation  1  h  after  drug  administration  and  the  interval  between  the  onset  of  labor  and
delivery.
Results: No  signiﬁcant  differences  were  observed  in  the  duration  of  phases  of  labor  between
the two  groups.  No  signiﬁcant  differences  were  found  between  the  groups  in  Apgar  scores  at  1
and 5  min.  No  maternal  adverse  effects  were  observed  or  reported  due  to  the  use  of  hyoscine
butylbromide  or  the  placebo.  On  the  ﬁrst  phase  of  primigravidas  it  shortens  the  ﬁrst  labor  phase
up to  159.1  ±  84  min  vs.  the  control  group  (p  =  0.002).
Conclusion:  Hyoscine  butylbromide  oxytocin  shortens  the  duration  of  labor  in  term  primigravida
pregnancies.  No  side  effects  were  reported.
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abor  is  a  sequential  physiological  event.  It  integrates
hanges  that  will  take  place  in  the  myometrium,  decidua
nd  cervix,  which  occur  over  a  period  of  days,  or  even
eeks.  Biochemical  changes  appear  before  the  onset  of
terine  contractions  and  cervical  dilatation.1 Labor  at  term,
upposes  the  liberation  of  inhibitor  factors  which  affect
regnancy  and  the  myometrium,  which  sets  off  an  active
rocess  through  uterine  stimulators.2 Different  substances
asson Doyma México S.A. All rights reserved.
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uEffect  of  hyoscine  butylbromide  on  duration  of  labor  
intervene  during  labor,  like  prostaglandins  (PG),  estrogens
and  oxytocin,  among  others.
It  was  customary  to  follow  the  natural  evolution  of
labor  without  the  application  of  any  method  to  acceler-
ate  it  (passive  handling  of  labor),  either  that  or  with  the
use  of  medications  which  accelerate  it  (active  handling  of
labor).2
In  the  beginning  of  the  20th  century,  in  1906,  the  ﬁrst
uterotonic  was  discovered,  oxytocin.  It  was  not  until  1911
when  its  implementation  began  to  accelerate  labor.2 Oxy-
tocin  is  a  cyclic  nonapeptide  obtained  through  chemical
synthesis.  Its  synthetic  form  is  identical  to  that  of  a  hormone
stored  in  the  posterior  hypophysis,  it  stimulates  the  smooth
muscle  of  the  uterine  strongly  toward  the  end  of  the  preg-
nancy,  during  labor  and  immediately  after  childbirth.  During
this  phase,  oxytocin  receptors  in  the  myometrium  increase.
This  is  a  fast-acting  hormone,  with  a  latent  period  of  under
a  minute  after  intravenous  application  and  between  2  and
4  min  after  intramuscular  injection.3 In  the  active  phase
of  the  ﬁrst  period  of  labor,  oxytocin  is  commonly  used,  in
patients  who  require  it  in  order  to  cause  uterine  contractions
and  to  regularize  its  frequency.4
In  some  countries,  in  addition  to  the  above,  other  medi-
cations  have  been  used  to  shorten  labor,  such  as  drotaverin
and  hyoscine  N-butylbromide  (BBH).4 This  is  part  of  a  group
of  scopolamine  derivates,  which  are  muscarinic  antagonists
and  have  antispasmodic  effects.  It  inhibits  cholinergic  activ-
ity  in  abdominal  and  pelvis  parasympathetic  lymph  nodes,
having  an  effect  on  the  smooth  muscle  of  the  digestive
tract,  urinary,  biliary,  female  sexual  organ  and  especially
over  the  uterine--cervical  plexus,5 which  explains  its  effect
in  cervical  dilatation.  However,  this  has  not  yet  been  clearly
stated.6
This  medication  does  not  have  effects  over  uterine  con-
tractibility;  it  does  not  go  through  the  blood--brain  barrier
and  its  ﬁxation  to  proteins  is  very  low,  with  a  very  quick
distribution;  after  intravenous  administration  the  time  of
action  is  around  10  min,  with  a  peak  from  20  to  60  min  and  an
average  life  ranging  from  4  to  5  h.7 Its  main  way  of  excretion
is  renal.  No  adverse  effects  during  pregnancy  or  lactation
have  been  proven;  however,  its  use  is  recommended  with
caution  under  the  ﬁrst  trimester.  Side  effects  include:  dry
mouth,  facial  ﬂushing,  intermittent  loss  of  accommodation
reﬂexes,  urinary  retention  and  constipation.6
There  have  been  few  studies  in  which  the  use  of  BBH
was  evaluated  to  shorten  labor.  These  have  reported  the
reduction  of  labor  time  compared  to  the  control  group  which
received  placebo,5 and  one  study  compared  its  effective-
ness  versus  oxytocin.8 The  objective  of  our  study  was  to
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Table  1  Comparison  of  the  characteristics  of  both  groups.
Placebo  
Age  (years)  25.37  ±  6.98  
Nulliparous  13  (30.23%)  
Multiparous  30  (69.77%)  
Uterine fundus  (cm)  32.72  ±  1.821  
Estimated fetal  weight  (g)  3220.93  ±  255.004  
Johnson method  (g)  3262.588  ±  294.40  31
ompare  the  efﬁcacy  and  safety  of  BBH  versus  placebo  dur-
ng  labor.
aterials and methods
 randomized  experimental  study  was  designed  in  which
atients  older  than  18  years  were  included,  with  a  term
regnancy  (37--42  weeks),  independent  from  the  parity  with
ephalic  presentation,  with  a  clinically  adequate  pelvis  for
abor,  where  there  was  no  evidence  of  macrosomia  (esti-
ated  fetal  weight  over  4000  g)  and  who  were  in  the  ﬁrst
eriod  of  labor  in  the  active  phase  (dilatation  of  4  cm  or
ore)  with  regular  uterine  activity  (3--4  contractions  in
0  min).  We  excluded  all  patients  who  needed  to  complete
hildbirth  abdominally  due  to  different  causes.
Patients  who  were  eligible  for  this  study  were  chosen  ran-
omly  to  receive  active  treatment  with  BBH  versus  a  placebo
sing  a sampling  of  two  proportions,  in  an  inﬁnite  popula-
ion,  with  a  potency  of  90%  to  detect  the  difference  of  30%
mong  the  study  groups;  a  statistically  signiﬁcant  level  of
.05  was  established.  Over  these  premises  a sample  size  of
0  patients  per  group  was  calculated.
The  study  included  a  total  of  86  women  who  met  the
nclusion  criteria  and  who  went  to  the  Emergency  Service
f  the  ‘‘Dr.  José  E.  González’’  University  Hospital  for  the
esolution  of  their  pregnancy  between  June  2009  and  July
010.  All  patients  signed  an  informed  consent.
The  patients  were  randomly  distributed  into  one  of  the
wo  groups:  the  cases  group,  with  43  patients  who  were
dministered  20  mg  of  BBH  (diluted  in  9  ml  of  saline  solu-
ion)  intravenously  on  two  occasions  with  an  interval  of  1  h,
nd  the  control  group  with  43  patients  who  were  adminis-
ered  a placebo  (10  ml  of  saline  solution)  at  a  similar  dosage
nd  interval.  After  every  dose,  fetal  and  maternal  car-
iac  frequency  monitoring  was  performed  and  patients  were
uestioned  about  side  effects.  Labor  progress  was  evalu-
ted  in  a  conventional  manner,  monitoring  the  time  of  every
eriod  of  labor,  in  addition  to  the  events  occurring  during  its
volution  (spontaneous  rupture  of  membranes,  analgesia,
orceps  application,  etc.).  Also  weight  at  birth,  Apgar  and
apurro  were  evaluated.  Maternal  and  fetal  complications
ere  evaluated  (uterine  atony,  vaginal  and  perineal  tears,
tc.)  after  childbirth.  Central  tendency  measurements  were
tilized  and  the  duration  of  every  period  of  labor  was  deter-
ined.
The  differences  between  groups  were  compared  with  2
r  Fisher’s  exact  test  in  the  case  of  categorical  variables  and
ith  the  Student’s  t-test  for  continuous  variables.
BBH  p
25.65  ±  6.555  0.848
12  (27.9%)  0.499
31  (72.1%)  0.499
32.581  ±  1.845  0.726
3228.581  ±  217.226  0.881
3250.325  ±  292.241  0.847
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Table  2  Comparison  in  labor  evolution.
Placebo  BBH  p
1st.  period  (min) 139.93  ±  92.484 151.186  ±  84.657  0.577
2nd. period  (min)  15.581  ±  9.334  13.186  ±  6.351  0.167
3rd. period  (min)  6.418  ±  3.265  6.581  ±  3.724  0.82
Table  3  Perinatal  results.
Placebo  BBH  p
Fetal  weight  (g)  3248.139  ±  374.837  3185.581  ±  397.28  0.454
Size (cm)  50.720  ±  1.992  50.767  ±  1.776  0.908
Silverman 0  (100%)  0  (100%)  0
Apgar 1  min  8.209  ±  0.666  8.209  ±  0.406  0
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mApgar 5  min  9.186  ±  0.444  
Capurro (weeks)  39.146  ±  1.273  
esults
 total  of  90  patients  were  included  in  the  study.  Of  these,
e  discarded  two  patients  from  the  case  group  and  two
rom  the  control  group,  because  it  became  necessary  for
hem  to  have  an  abdominal  birth.  The  cervical  conditions  of
he  placebo  group  upon  entry  were:  dilation  of  5.6  ±  1.5  cm,
3  ±  11%  effacement  and  Bishop  Index  of  8.8  ±  1.2.  And  in
he  BBH  group  they  were:  dilation  of  5.2  ±  1.3  cm,  72  ±  11%
ffacement  and  Bishop  Index  of  8.6  ±  1.2.  Upon  compari-
on  of  these  variables,  there  was  no  statistically  signiﬁcant
ifference,  which  indicates  that  these  two  groups  were
omogenous  (Table  1).
Regarding  the  results  of  the  duration  of  labor,  the  ﬁrst
eriod  of  labor,  evaluated  in  minutes,  was  139.93  ±  92.4  in
he  placebo  group  versus  151.186  ±  84.6  in  the  BBH  group
p  = NS).  The  second  period  of  labor  had  a  duration  of
5.5  ±  9.33  min  in  the  ﬁrst  group  and  13.18  ±  6.35  min  in  the
econd  (p  =  NS).  Finally,  the  third  period  registered  a  time  of
.4  ±  3.2  min  in  the  placebo  group  and  6.5  ±  3.7  min  in  the
BH  group.  We  were  unable  to  ﬁnd  a  statistically  signiﬁcant
ifference  (Table  2).
Upon  separating  the  groups  by  number  of  pregnancies,  we
ound  that  the  BBH  group  had  a  159.1  ±  84  min  time  for  the
rst  phase  of  labor,  with  signiﬁcant  difference  of  p  =  0.002
ompared  to  the  control  group  (262.5  ±  92  min).
Concerning  the  perinatal  results,  we  observed  a  fetal
eight  of  3248  ±  374  g,  a  length  of  50.7  ±  1.9  cm  and
9.14  ±  1.2  Capurro  weeks  in  the  placebo  group,  and  a
etal  weight  of  3185.5  ±  397  g,  a  length  of  50.7  ±  1.7  cm
nd  38.9  ±  1.1  Capurro  weeks  in  the  BBH  group.  We  were
nable  to  ﬁnd  a  statistically  signiﬁcant  difference.  Concern-
ng  the  condition  of  the  babies  immediately  after  birth,  we
eported  an  Apgar  score  at  the  ﬁrst  minute  of  8.2  ±  0.6  and
.1  ±  0.4  at  5  min  in  the  control  group,  and  8.2  ±  0.4  at  the
rst  minute  and  9  ±  0  at  5  min  in  the  BBH  group.  We  were
nable  to  ﬁnd  a  statistically  signiﬁcant  difference  (Table  3).iscussion
revious  studies  performed  with  BBH  have  reported  results
hich  vary  from  no  difference  in  cervical  dilation  time
d
d
s
t9  ±  0  0.007
38.986  ±  1.180  0.547
o  decreases  greater  than  2  h.  Aggarwal  et  al.7 performed
 study  in  which  they  found  that  in  addition  to  a  35.6%
iminishment  in  the  perception  of  pain  during  labor  due
o  the  use  of  intravenous  BBH,  the  ﬁrst  period  of  labor
as  reduced  in  a signiﬁcant  way,  from  8  h  16  min  in  the
ontrol  group,  to  3  h  46  min  in  the  BBH  group.  Samals
t  al.  concluded  that  using  intravenous  BBH,  at  a  dose  of
0  mg,  was  able  to  diminish  the  effort  of  labor  by  up  to
2%.9
Other  authors  recently  compared  the  use  of  this  pharma-
eutic  to  oxytocin  without  ﬁnding  a  statistically  signiﬁcant
ifference  in  the  effort  of  labor,10 which  is  the  reason  the
se  of  this  medication  should  be  considered  as  an  option
or  primigravid  patients  which,  for  whatever  reason,  cannot
eceive  oxytocin.
We can  make  a  recommendation  for  the  use  of  this  phar-
aceutic  in  patients  with  the  results  obtained  by  separately
valuating  groups  of  primigravid  and  multigravid  patients
hich  received  BBH  vs.  a  placebo;  with  regard  to  the  mul-
iparous,  there  was  no  signiﬁcant  difference  found  between
ny  of  the  groups.
Just  like  in  other  studies,11 our  results  show  no  adverse
ffects  on  the  fetus,  which  were  evaluated  by  the  APGAR  at
 and  5  min.
onclusions
ased  on  the  results  obtained  in  our  investigation,  we  can
onclude  that  although  we  were  not  able  to  prove  a  sta-
istically  signiﬁcant  decrease  in  the  effort  of  labor  in  both
roups,  we  did  demonstrate  that  when  the  groups  of  prim-
gravidas  and  multigravidas  are  compared  separately,  the
rimigravida  BBH  group  showed  a  statistically  signiﬁcant  dif-
erence,  with  a  p  of  0.002.
Based  on  the  previous  studies,  we  can  make  a  recom-
endation  for  the  use  of  BBH  in  primigravid  patients,  also
emonstrating  that  the  administration  of  this  product  is  safe
uring  pregnancy,  since  there  were  no  adverse  effects  pre-
ented  during  its  administration,  or  among  the  babies  in  all
he  studied  population.
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